Orally active αvβ3 integrin inhibitor MK‑0429 reduces melanoma metastasis

Pickarski,Maureen; Gleason,Alexa; Bednar,Bohumil; Duong,Le T.

doi:10.3892/or.2015.3910

Orally active αvβ3 integrin inhibitor MK‑0429 reduces melanoma metastasis

Authors:
- Maureen Pickarski
- Alexa Gleason
- Bohumil Bednar
- Le T. Duong
View Affiliations

Affiliations: Bone Biology, Merck Research Laboratories, West Point, PA 19486, USA, Imaging, Merck Research Laboratories, West Point, PA 19486, USA
Published online on: April 9, 2015 https://doi.org/10.3892/or.2015.3910
Pages: 2737-2745
Copyright: © Pickarski et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma remains one of the most aggressive types of cancer with a historically low survival rate. The αvβ3 integrin is involved in the progression of malignant melanoma. In the present study, the efficacy of MK-0429, a selective inhibitor of the αvβ3 integrin, was evaluated for its potential in the prevention of melanoma metastasis. Female B6D2F1 mice injected via the tail vein with murine B16F10 melanoma developed lung metastases within ~10 days. In the first experiment, the prevention of lung metastasis was assessed in the model treated with either vehicle, MK-0429 at 100 and 300 mg/kg orally twice daily or cyclophosphamide at 300 mg/kg, i.p. once daily. Study endpoints included determination of the study time period to achieve metastasis in lungs in this model, evaluation of the health effects on the study animals, the total number of lung colonies identified and lung tumor area. Unlike cyclophosphamide, the MK-0429 treatment did not lead to a significant weight reduction in mice. MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle. The second experiment employed B16F10 luciferase‑expressing cells to examine the de novo progression of melanoma metastasis over 15 days with bioluminescent imaging of mice treated with MK-0429 at 300 mg/kg as compared to the vehicle. Tumor burden progressively advanced in the lungs of the B16F10-treated animals. However, MK-0429 reduced the progression of ventral and dorsal lung metastases by 22 and 38%, respectively, as compared to the vehicle, by study completion. Quantification of ex vivo tumor burden showed a 30-40% reduction in lung colonies by MK-0429. The two studies collectively demonstrated that MK-0429 was safe and efficacious in significantly decreasing melanoma metastasis in the lungs. The results emphasized the potential of MK-0429 as a novel, therapeutic agent for the prevention of metastatic melanoma.

View Figures

View References

1	Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 19:3622–3634. 2001.PubMed/NCBI
2	Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant melanoma. Mayo Clin Proc. 81:500–507. 2006. View Article : Google Scholar : PubMed/NCBI
3	Culos KA and Cuellar S: Novel targets in the treatment of advanced melanoma: New first-line treatment options. Ann Pharmacother. 47:519–526. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ma C and Armstrong AW: Severe adverse events from the treatment of advanced melanoma: A systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat. 25:401–408. 2014. View Article : Google Scholar
5	Kuphal S, Bauer R and Bosserhoff AK: Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 24:195–222. 2005. View Article : Google Scholar : PubMed/NCBI
6	Marshall JF, Rutherford DC, Happerfield L, Hanby A, McCartney AC, Newton-Bishop J and Hart IR: Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br J Cancer. 77:522–529. 1998. View Article : Google Scholar : PubMed/NCBI
7	Nip J and Brodt P: The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. Cancer Metastasis Rev. 14:241–252. 1995. View Article : Google Scholar : PubMed/NCBI
8	Johnson JP: Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 18:345–357. 1999. View Article : Google Scholar
9	Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar
10	Jin H and Varner J: Integrins: Roles in cancer development and as treatment targets. Br J Cancer. 90:561–565. 2004. View Article : Google Scholar : PubMed/NCBI
11	Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA and Brooks PC: Integrin α_vβ₃ promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 59:2724–2730. 1999.PubMed/NCBI
12	Smith SD, Enge M, Bao W, Thullberg M, Costa TD, Olofsson H, Gashi B, Selivanova G and Strömblad S: Protein kinase Cα (PKCα) regulates p53 localization and melanoma cell survival downstream of integrin αv in three-dimensional collagen and in vivo. J Biol Chem. 287:29336–29347. 2012. View Article : Google Scholar : PubMed/NCBI
13	Bao W and Strömblad S: Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol. 167:745–756. 2004. View Article : Google Scholar : PubMed/NCBI
14	Horton MA: The alpha v beta 3 integrin ‘vitronectin receptor’. Int J Biochem Cell Biol. 29:721–725. 1997. View Article : Google Scholar : PubMed/NCBI
15	Eble: Integrin-Ligand Interaction. R.G. Landes Company; Georgetown: 1997
16	Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA and Herlyn M: Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol. 153:1435–1442. 1998. View Article : Google Scholar : PubMed/NCBI
17	Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E and Nakada MT: Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 62:2824–2833. 2002.PubMed/NCBI
18	Oliva IB, Coelho RM, Barcellos GG, Saldanha-Gama R, Wermelinger LS, Marcinkiewicz C, Benedeta Zingali R and Barja-Fidalgo C: Effect of RGD-disintegrins on melanoma cell growth and metastasis: Involvement of the actin cytoskeleton, FAK and c-Fos. Toxicon. 50:1053–1063. 2007. View Article : Google Scholar : PubMed/NCBI
19	Kang IC, Kim DS, Jang Y and Chung KH: Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis. Biochem Biophys Res Commun. 275:169–173. 2000. View Article : Google Scholar : PubMed/NCBI
20	Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong T, Fernandez-Metzler C, Gentile MA, Fisher JE, Hartman GD, et al: Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem. 46:4790–4798. 2003. View Article : Google Scholar : PubMed/NCBI
21	Murphy MG, Cerchio K, Stoch SA, Gottesdiener K, Wu M and Recker R; L-000845704 Study Group: Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 90:2022–2028. 2005. View Article : Google Scholar : PubMed/NCBI
22	Rosenthal MA, Davidson P, Rolland F, Campone M, Xue L, Han TH, Mehta A, Berd Y, He W and Lombardi A: Evaluation of the safety, pharmacokinetics and treatment effects of an α_vβ₃ integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol. 6:42–48. 2010. View Article : Google Scholar : PubMed/NCBI
23	Simon KO, Nutt EM, Abraham DG, Rodan GA and Duong LT: The alphavbeta3 integrin regulates alpha5beta1-mediated cell migration toward fibronectin. J Biol Chem. 272:29380–29389. 1997. View Article : Google Scholar : PubMed/NCBI
24	Abraham DG, Nutt EM, Bednar RA, Bednar B, Gould RJ and Duong LT: Arginine-glycine-aspartic acid mimics can identify a transitional activation state of recombinant alphaIIb beta3 in human embryonic kidney 293 cells. Mol Pharmacol. 52:227–236. 1997.PubMed/NCBI
25	Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, Buono C, Ho G, Blusztajn A, Cuneo G, Zhang J, et al: Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol. 12:488–499. 2010. View Article : Google Scholar
26	Pickarski M, Hayami T, Zhuo Y and Duong T: Molecular changes in articular cartilage and subchondral bone in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. BMC Musculoskelet Disord. 12:1972011. View Article : Google Scholar : PubMed/NCBI
27	Fidler IJ: Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35:218–224. 1975.PubMed/NCBI
28	Fidler IJ and Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science. 197:893–895. 1977. View Article : Google Scholar : PubMed/NCBI
29	Cowden Dahl KD, Robertson SE, Weaver VM and Simon MC: Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell. 16:1901–1912. 2005. View Article : Google Scholar : PubMed/NCBI
30	Barczyk M, Carracedo S and Gullberg D: Integrins. Cell Tissue Res. 339:269–280. 2010. View Article : Google Scholar
31	Giancotti FG and Ruoslahti E: Integrin signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
32	Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D IV, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, et al: Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol. 30:562–567. 1999. View Article : Google Scholar : PubMed/NCBI
33	Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M and Buck CA: Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression. Cancer Res. 50:6757–6764. 1990.PubMed/NCBI
34	Brooks PC: Role of integrins in angiogenesis. Eur J Cancer. 32A:2423–2429. 1996. View Article : Google Scholar : PubMed/NCBI
35	Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 85:683–693. 1996. View Article : Google Scholar : PubMed/NCBI
36	Danen EHJ: Integrin signaling as a cancer drug target. ISRN Cell Biol. 2013:1351642013.http://dx.doi.org/10.1155/2013/135164. Accessed: Jan 10, 2015. View Article : Google Scholar
37	Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O’Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, et al: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 26:5610–5617. 2008. View Article : Google Scholar : PubMed/NCBI
38	Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, et al: A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res. 22:294–301. 2012. View Article : Google Scholar : PubMed/NCBI
39	Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ and Cheresh DA: Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 6:3056–3061. 2000.PubMed/NCBI
40	Mcneel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, et al: Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res. 11:7851–7860. 2005. View Article : Google Scholar : PubMed/NCBI
41	Hersey P, Sosman J, O’Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, et al: Etaracizumab Melanoma Study Group: A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α_vβ₃, ± dacarbazine in patients with stage IV metastatic melanoma. Cancer. 116:1526–1534. 2010. View Article : Google Scholar : PubMed/NCBI
42	Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, et al: Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 15:392–400. 2009. View Article : Google Scholar : PubMed/NCBI
43	Girotti MR, Saturno G, Lorigan P and Marais R: No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol. 8:1140–1158. 2014. View Article : Google Scholar : PubMed/NCBI